Evommune Inc (EVMN)

May 04, 2026

Certain Rights of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com

May 04, 2026

May 02, 2026

Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell - MarketBeat

May 02, 2026

May 01, 2026

Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo

May 01, 2026

May 01, 2026

Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat

May 01, 2026

May 01, 2026

Stifel initiated coverage on Evommune with a new price target - Quantisnow

May 01, 2026

May 01, 2026

Stifel Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $54 - Moomoo

May 01, 2026

Apr 30, 2026

Evommune and BillionToOne climb on trading debut - MSN

Apr 30, 2026

Apr 30, 2026

Evommune surges on mid-stage trial win for eczema therapy - MSN

Apr 30, 2026

Apr 30, 2026

Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Apr 30, 2026

Apr 28, 2026

Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat

Apr 28, 2026

Apr 27, 2026

[EFFECT] Evommune, Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 25, 2026

Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis - TipRanks

Apr 25, 2026

Apr 24, 2026

Evommune (NYSE: EVMN) registers 4.49M shares for resale by investors - Stock Titan

Apr 24, 2026

Apr 24, 2026

EVMN Options Chain — NYSE:EVMN - TradingView

Apr 24, 2026

Apr 24, 2026

Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo

Apr 24, 2026

Apr 24, 2026

Evommune, Inc. Common Stock (NY: EVMN - FinancialContent

Apr 24, 2026

Apr 23, 2026

EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 23, 2026

Apr 23, 2026

Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm

Apr 23, 2026

Apr 23, 2026

EVMN Evommune reports wider Q4 2025 loss than analyst projections, shares dip modestly on soft quarterly earnings.Market Hype Signals - UBND thành phố Hải Phòng

Apr 23, 2026

Apr 21, 2026

Evommune (EVMN) details 2026 director votes and CEO pay in proxy - Stock Titan

Apr 21, 2026

Apr 20, 2026

Why is Evommune (EVMN) stock going up today (Institutional Selling) 2026-04-20AI Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 20, 2026

Apr 17, 2026

Evommune (EVMN) Chief Scientific Officer awarded 69,315 stock options at $26.77 - Stock Titan

Apr 17, 2026

Apr 17, 2026

Evommune (EVMN) grants 73,892 stock options to development chief - Stock Titan

Apr 17, 2026

Apr 17, 2026

[Form 4] Evommune, Inc. Insider Trading Activity - Stock Titan

Apr 17, 2026

Apr 17, 2026

Evommune (EVMN) grants CFO 98,946 options at $26.77 strike - Stock Titan

Apr 17, 2026

Apr 17, 2026

Evommune (EVMN) grants 115,279 stock options to chief legal officer - Stock Titan

Apr 17, 2026

Apr 17, 2026

Evommune (EVMN) CEO Luis C. Pena receives 291,420 stock option grant - Stock Titan

Apr 17, 2026

Apr 17, 2026

Evommune Incprospectus filed for resale of up to 4.5 million shares of Evommune common stock by selling stockholdersSEC filing - marketscreener.com

Apr 17, 2026

Apr 17, 2026

Evommune (NYSE: EVMN) investors file to resell 4.49M previously issued shares - Stock Titan

Apr 17, 2026

Apr 17, 2026

Evommune stock price target reaffirmed at $50 by H.C. Wainwright - Investing.com South Africa

Apr 17, 2026

Apr 17, 2026

H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo

Apr 17, 2026

Apr 16, 2026

Velan Capital Investment Management LP's Evommune Inc(EVMN) Holding History - GuruFocus

Apr 16, 2026

Apr 14, 2026

Evommune Makes Case For MRGPRX2 Inhibition in Migraine - Citeline News & Insights

Apr 14, 2026

Apr 14, 2026

MRGPRX2: A Novel Target in Migraine Treatment – EVO756’s Potential in Migraine Prophylaxis Explained - Minichart

Apr 14, 2026

Apr 14, 2026

William Blair Maintains Evommune(EVMN.US) With Buy Rating - Moomoo

Apr 14, 2026

Apr 13, 2026

Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating - TipRanks

Apr 13, 2026

Apr 13, 2026

Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy - TipRanks

Apr 13, 2026

Apr 13, 2026

Evommune (EVMN) advances oral MRGPRX2 migraine drug EVO756 toward Phase 2b - Stock Titan

Apr 13, 2026

Apr 11, 2026

RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN) - The Globe and Mail

Apr 11, 2026

Apr 10, 2026

Evommune (NYSE:EVMN) Stock Price Down 7.2%Here's Why - MarketBeat

Apr 10, 2026

Apr 10, 2026

Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says - marketscreener.com

Apr 10, 2026

Apr 10, 2026

Today's Analyst Rating Update for EVMN: Maintained at Outperform - GuruFocus

Apr 10, 2026

Apr 10, 2026

Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat

Apr 10, 2026

Apr 10, 2026

RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo

Apr 10, 2026

Apr 09, 2026

Evommune (EVMN) Institutional Ownership 2026 - MarketBeat

Apr 09, 2026

Apr 07, 2026

Evommune (NYSE:EVMN) Advances Within Biotechnology Research And Development - Kalkine Media

Apr 07, 2026

Apr 07, 2026

Oppenheimer Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $50 - Moomoo

Apr 07, 2026

Apr 07, 2026

Evommune (NYSE:EVMN) Shares Up 4.7%Here's What Happened - MarketBeat

Apr 07, 2026

Apr 07, 2026

Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN) - MarketBeat

Apr 07, 2026

Apr 07, 2026

Evommune bucked biotech IPO drought and is focused on the long game - Pharma Voice

Apr 07, 2026